Table 10 The PK parameters for Equation11modeling doxorubicinol for Gianni et al. [[27]] with paclitaxel present

1,2

$14.0\left|\frac{1+10.6X_{\mathit{\text{DOL}},2}^{0.72}}{1+4.54X_{\mathit{\text{DOL}},2}^{1.67}}\right|\left|1-\frac{0.00008X_{\mathit{\text{PTX}},1}^{0.39}}{1+0.00007X_{\mathit{\text{PTX}},1}^{3.64}}-\frac{0.0368X_{\mathit{\text{PTX}},2}^{3.10}}{1+0.00001X_{\mathit{\text{PTX}},2}^{0.60}}\right|$

1,3

$3.92\left|1+0.115X_{\mathit{\text{DOL}},1}^{0.55}\right|\left|\frac{1+1.02X_{\mathit{\text{DOL}},3}^{1.52}}{1+0.0482X_{\mathit{\text{DOL}},3}^{2.43}}\right|\left|1-\frac{0.00095X_{\mathit{\text{PTX}},1}^{3.26}}{1+0.00006X_{\mathit{\text{PTX}},1}^{5.09}}-\frac{0.0003X_{\mathit{\text{PTX}},3}^{2.64}}{1+0.0001X_{\mathit{\text{PTX}},3}^{2.58}}\right|$

2,0

$8.58\left|1-0.0167X_{\mathit{\text{DOL}},2}^{1.55}\right|\left|1-\frac{0.0426X_{\mathit{\text{PTX}},2}^{0.457}}{1+0.00004X_{\mathit{\text{PTX}},2}^{2.28}}\right|$

2,1

$3.90\left|1+0.0646X_{\mathit{\text{DOL}},2}^{1.18}\right|\left|\frac{1+0.128X_{\mathit{\text{DOL}},1}^{0.95}}{1+3.97X_{\mathit{\text{DOL}},1}^{1.07}}\right|\left|1+\frac{0.0223X_{\mathit{\text{PTX}},1}^{2.22}}{1+0.00004X_{\mathit{\text{PTX}},1}^{0.21}}+\frac{1.11X_{\mathit{\text{PTX}},2}^{0.52}}{1+0.00001X_{\mathit{\text{PTX}},2}^{1.12}}\right|$

3,1

$0.0594\left|1+0.0073X_{\mathit{\text{DOL}},3}^{2.26}\right|\left|\frac{1-6.94X_{\mathit{\text{DOL}},1}^{1.17}}{1+3.19X_{\mathit{\text{DOL}},1}^{0.96}}\right|\left|1-\frac{0.00003X_{\mathit{\text{PTX}},1}^{2.50}}{1+0.00002X_{\mathit{\text{PTX}},1}^{0.60}}+\frac{0.0010X_{\mathit{\text{PTX}},3}^{3.31}}{1+0.00004X_{\mathit{\text{PTX}},3}^{5.16}}\right|$